1 Histological subtypes and survival of malignant mesothelioma patients.. Pr Francoise Galateau-Sallé 1,2, 3 N. Le Stang 1,2, P. Astoul 2,3, P. Brochard 2,3, P. Rolland 2,3, JC. Pairon 2,3, G. Launoy 1, E. Imbernon 3 A. Gilg soit Ilg 3, M.Goldberg 2,3 ERI 3 INSERM 1 MESONAT Register 2 PNSM 3
2 Background Survival DMM is a very heterogeneous disease considered to be rapidly fatal with a median survival of less than one year from diagnosis. The worldwide incidence of MM parallels the exploitation and the use of asbestos after a long latency (30 to 40 years-mean latency 40 yrs). The lack of obvious early symptoms means that MM remains undetectable until clinical symptoms manifest and as a result is diagnosed late in disease progression. Although the prognostic is extremely poor in general, individual patients might live for an unexpectedly long time.
3 Background It is notorious that MM is refractory to most of the different treatment modalities available. Nowadays, the search for clinician guidelines in clinical decision is important with the emergence of newer therapies. The use of prognostic factors is hampered by the fact that a good clinical outcome is difficult to predict.
4 Variables are: Age Sex PS Background Prognostic factors for survival Presence of chest pain, dyspnea Duration of symptoms Asbestos exposure Staging of disease [IMIG staging] Histological type Immunohistochemical markers Molecular markers Genomic profile
5 Background Prognostic factors important for survival A list of previous studies on survival of MM patients stated that sex, age, stage, asbestos exposure and treatment were important prognostic factors: Chahinian et al, Ann Intern Med 1982, 96: Ribak & Selikoff Br J ind Med, 1988;45:182 Spirtas et al, Int J Cancer 1988;41: histologically confirmed MM patients ( women and asbestos exposure) Tammilehto Lung Cancer Lung Cancer 1992; 8: Simmon et al, Br J Cancer 1994;69: Br J Cancer 1994;69: But conflicting results were published and were related to single institution trials with small numbers of patients, variable eligibility criteria and statistical methodology used.
6 More recently : Background Factors predictive of survival Curran et al, J Clin Oncol 1998; 16: showed the importance of histologic subtype as a prognostic factor and identified five prognostic factors important for survival of patients PS, WBC count, certainty of the histological diagnosis, gender and histology Edwards et al, Thorax 2000;55: validate the prognostic factors EORTC and CALGB Herndon et al, Chest 1998;113: Univariate: Male sex, older age, weight loss>5kg, poor PS, Low Haem (<14g/l), leucocytosis (>8.3x10), Thrombocytosis (>400x10) Multivariate: Male sex, poor PS, Low Haem, Leucocytosis, non epithelial subtype Baas, Lung Cancer 2007;57: S24-S29 Lung Cancer 2007;57: S24-S29 showed that the discovery of new treatment modalities such as pemetrexed in combination with cisplatin were associated with extremely promising results and stressed the emergency to define poor and good prognosis group.
7 MESONAT registry French population ~60 millions Register all mesothelioma cases from France MESOPATH Repository [ cases & collection of paraffin embedded blocks] College of pathologists -certification of MM cases with a standardized procedure Frozen tissue bank Biological ressources center CRB Inserm n 8 Pilot centre for exposure and aetiology Clinical ascertainment center Coordination center PNSM- NIH INVs Recognition of MM as a compensable occupational disease Multidisciplinary approach
8 MESONAT REGISTRY Design of the study To evaluate the prognostic role of age, sex, time of diagnosis, and asbestos exposure variables The prognostic role of histological subtypes The possible role of Ipox and genomics as a diagnostic, prognostic and predictive tool for outcome and management of MM. In a large population of patients from the Mesonat registry/pnsm
9 Material of the study 2045 cases were retrieved from the files of the MESONAT Registry through repeated inquiries among various sources have been validated according to the standardized procedure of certification of the Mesopath group including H&E and Ipox analysis ( 2 positive /2 negative markers). (Goldberg M, et al,. The French National Mesothelioma Surveillance Program. Occup Environ Med 2006, Feb 2006). Cases were classified as definitively meso or other tumors of mesothelial origin Occupational histories were evaluated by a group of asbestos epidemiological experts using a standardized questionnaire directly with the subject during a faceto-face interview.
10 Material of the study Cases were selected from January 1998 to October 25 th, Clinical features were identified according to a standardized questionnaire Overall survival was calculated from the date of initial biopsy based on the Kaplan and Meyer method.
11 Results 1514 cases have been validated according to the standardized procedure of certification of the Mesopath group: 1207 M (80%) 307 F (20%) Median age at the initial diagnosis 71 years (Min-Max: yrs) Asbestos exposure 920 cases/ 1092 (84%) Unknown asbestos exposure (28%) 220 cases (14.5%) were classified according to the WHO classification IARC Lyon 2004: 145 subtypes features (deciduoid/clear cells etc /osteocartilageneous etc 54 rare variants (desmoplastic/lymphohistiocytoid/ pleomorphic ) 21 other mesothelial tumors ( Well Differentiated Papillary Mesothelioma, adenomatoid tumor).
12 Results Clinical features Clinical symptoms for pleural MM (from 49% of the cases) were: Pain 24% ( n= 181) Fatigue 16% (=119) Loss of weight 12% (n=87) Dyspnea 20% ( n=148) Unilateral pleural effusion 77% (n=571) Diffuse pleural thickening or multiples nodules 59% ( n=442) Localized mass 6% (n= 43) Pneumothorax 3% (n= 19) Hyalin fibrous plaques 15% (n=113)
13 Results Histological subtypes and rare variants % of cases according to histological subtypes, WHO classification, 2004 DMM histological subtypes. Epithelioid 78% (n=1168 ) Biphasic 12% (n=180) Sarcomatoid 7% (n=111) Desmoplastic 2% (n=34) Biphasi c 12% Sarcom atoid 7% Desmo plastic 2% Adeno matoid <1% WDPM 1% Other tumor of mesothelial origin WDPM 1% (n=15) Adenomatoid tumor<1% (n=6) Epitheli oid 78%
14 Results overall survival Median survival: 11 months 2 years survival: 15% CI 95% = [12% ; 18%] Spirtas et al, 1988, Int J Cancer 41: Overall survival was 7 months
15 Results overall survival by gender Median survival 2 years survival Male: 11 months 16% CI 95% = [13% ; 19%] Female: 10 months 13% CI 95% = [7% ; 19%]
16 Results overall survival by asbestos exposure Median survival 2 years survival Exposure: 11 months 17% CI 95% = [14% ; 20%] No exposure: 11 months 28% CI 95% = [24% ; 32%]
17 Results overall survival by age distribution Median survival 2 years survival <50 yrs 16 months 24% CI 95% = [8% ; 40%] 50!age!69 12 months 19% CI 95% = [14% ; 23%] "70 yrs 9 months 12% CI 95% = [9% ; 15%]
18 Results overall survival by histological subtype Median survival 2 years survival Epithelioid: 12 months 18% CI 95% = [14% ; 21%] Biphasic: 8 months 7% CI 95% = [2% ; 12%] Sarcomatoid: 5 months 9% CI 95% = [2% ; 16%] Desmoplastic: 5 months 4% CI 95% = [0% ; 12%]
19 Desmoplastic type of MM Mangano et al, Am J Clin Pathol, 1998;110:191-9 Churg et al, Am J Surg Pathol, 2000; 24: Cagle and Churg, Arch Pathol Lab Med, 2005, 129: Datas were updated october 25, 2007; A Series of 34 cases Male n=33 (97%): Female n=1 (3%) Median age 70 years [40-92 years] Asbestos exposure 29 /31 (94%) Clinical features Pain 63 % (n=15) Fatigue 21 % ( n=5) Weight loss 21 % (n=5) Dyspnea 25% ( n=6) Unilateral pleural effusion 79% (n=19) Diffuse pleural thickening 71% (n=17) Hyalin fibrous plaques 25% (n=6) Pneumothorax 4% (n=1)
20 Desmoplastic type of MM histopathological features Histopathological features have been initially described by Mangano et al, Am J Clin Pathol 1998;110: No zonation ( cellularity away from effusion) Storiform pattern present Abrupt and haphazard transition in cellularity Bland necrosis Capillaries haphazardly distributed and inconspicuous Ipox: CK positive cells invading adipose tissue
21 Desmoplastic type of MM overall survival Median survival 2 years survival Median survival : 5 months 4% CI 95% = [0% ; 12%]
22 Lymphohistiocytoid variant of MM In 1988, LM was first described by Henderson et al. They showed that of 394 definite mesothelioma entered in the Australian Mesothelioma Surveillance Program Panel, three patients were presenting a striking resemblance with a Lymphoma. In 2000, Khalidi et al, described three additional cases They described pleural- based mass and a diffuse proliferation of large, atypical, spindle histiocytoid cells admixed with lymphocytes, plasma cells...
23 Lymphohistiocytoid variant of MM F. Galateau-Salle et al, a series of 22 cases Am J Surg Pathol,, 2007; 31:711-6 Datas were updated october 25, 2007; A Series of 20 cases Male n= 14 (70%): Female n=6 (30%) Median age 70 years [52-84 years] Asbestos exposure 14 /19 (74%) Clinical features Pain 56 % (n=9) Fatigue 44 % ( n=7) Weight loss 19 % (n=3) Dyspnea 25% ( n=4) Unilateral lymphocytic pleural effusion 75% (n=12) Diffuse pleural thickening or multiples nodules 75% (n=12) Localized mass 31% ( n=5)
24 Lymphohistiocytoid MM histological features Proliferation of large, spindle, histiocytoid, or ovoid discohesive cells intermingled with lymphoplasmacytic infiltrate Some Sternberg-like cells Calretinin positivity > 20%
25 Lymphohistiocytoid unusual variants of MM overall survival Median survival 2 years survival Epithelioid: 12 months 18% CI 95% = [14% ; 21%] Lymphohistiocytoid: 11 months 28 % CI 95% = [6% ; 50%] Sarcomatoid: 5 months 9% CI 95% = [2% ; 16%]
26 Lymphohistiocytoid unusual variants of MM overall survival Median survival 2 years survival Epithelioid: 12 months 18% CI 95% = [14% ; 21%] Lymphohistiocytoid: 11 months 28 % CI 95% = [6% ; 50%] Sarcomatoid: 5 months 9% CI 95% = [2% ; 16%]
27 Pleomorphic variant of MM Datas were updated october 25, 2007; A Series of 42 cases Male n=35 (83%): Female n=7 (17%) Median age 68 years [50-85 years] Asbestos exposure 28 /36 (78%) Clinical features Pain 42 % (n=11) Fatigue 54 % ( n=14) Weight loss 15 % (n=4) Dyspnea 27% ( n=7) Unilateral pleural effusion 77% (n=20) Diffuse pleural thickening or multiples nodules 54 % (n=14) Localized mass 16% ( n=3) Hyalin fibrous plaques 4% (n=1).
28 Pleomorphic variant of histological features MM Pleomorphic mesothelioma 3 9 calretinin 20 Proliferation of large and giant cells with pleomorphic nuclei % 73% 37% TTF-1 Calrétinin CK 5/6 TTF-1
29 Pleomorphic variant of MM overall survival Median survival 2 years survival: Epithelioid: 12 months 18% CI 95% = [14% ; 21%] Pleomorphic: 7 months 3% CI 95% = [0% ; 10%] Sarcomatoid: 5 months 9% CI 95% = [2% ; 16%]
30 Other tumor of mesothelial origin Well differentiated papillary mesothelioma Clinical features (10cases) Pain 0 % (n=0) Fatigue 20% % ( n=2) Weight loss 0 % (n=0) Dyspnea 30 % ( n=3) Unilateral pleural effusion 100 % (n=10) Multiples micronodules or focal thickening 40 % (n=4) Localized mass 0% (n=0) Hyalin fibrous plaques
31 Other tumor of mesothelial origin Well differentiated papillary mesothelioma New concept of superficial mesothelial proliferation Datas were not updated october 25, 2007; A Series of 15 cases Male n=10 (67 %): Female n=5 (33%) Median age 74 years [43-80 years] Asbestos exposure 11 /13 (85 %) Clinical features (10cases) Pain 0 % (n=0) Fatigue 20% % ( n=2) Weight loss 0 % (n=0) Dyspnea 30 % ( n=3) Unilateral pleural effusion 100 % (n=10) Multiples micronodules or focal thickening 40 % (n=4) Localized mass 0% (n=0) Hyalin fibrous plaques Histologically Superficial mesothelial proliferation of papillae with stout cores Without invasion in the adipose tissue or lung
33 Results overall survival of WDPM Median survival:63 months 2 years survival: 66% CI 95% = [38% ; 94%]
34 Different pathways in mesothelial carcinogenesis? WDPM Superficial mesothelial proliferation Invasive proliferation AMH Non invasive MM
35 Peritoneal malignant mesothelioma 3119 cases 155 cases have been validated definitively meso according to the standardized procedure of certification of the Mesopath group during the period : M (76%) F (24%) Median age at the initial diagnosis 70 years (Min-Max: yrs) Asbestos exposure 1349 cases/ 1775 (76%) Unknown asbestos exposure (43%) Peritoneal 5% Pleural location 94% Pericardial 0.3% Testis vaginalis < 0.2%
36 Peritoneal malignant mesothelioma overall survival Median survival 2 years survival Peritoneum 10 mois 33% CI 95% = [15% ; 51%] Pleura 11 mois 18% CI 95% = [16% ; 21%]
37 Peritoneal malignant mesothelioma overall survival by gender Median survival 2 years survival Male: 10 mois 19% CI 95% = [0% ; 38%] Female: - 59% CI 95% = [39% ; 79%]
38 Peritoneal malignant mesothelioma overall survival by age for female Median survival 2 years survival <50 yrs - 57% CI 95% = [23% ; 91%] 50!age!69 yrs 9 mois 36% CI 95% = [12% ; 60%] "70 yrs 5 mois 26% CI 95% = [2% ; 50%]
39 Plateform presentation USCAP meeting San Diego, 2007 Malignant pleural mesothelioma presenting as recurrent or spontaneous pneumothorax: a series of 35 cases cases validated according to the procedure of certification of the Mesopath group. (Goldberg M, et al,. The French National Mesothelioma Surveillance Program. Occup Environ Med 2006, Feb (H&E + Ipox ; 2 positive /2 negative markers). Cases were selected from January 1999 to December A series of 35/2463 MM cases (1.4%) presenting with spontaneous or recurrent pneumothoraces were selected. 2 PNO were excluded due to iatrogenic procedure. For these 35 cases, the diagnosis was not suspected at surgery and was made by histological examination.
40 Methods MM were classified according to the WHO classification Epithelioid, biphasic, sarcomatoid and desmoplastic. Occupational histories were evaluated by a group of asbestos epidemiological experts using a standardized questionnaire directly with the subject during a face-to-face interview. Smoking history in PNO MPM was evaluated according to: Number pack/years Current smoker/former smoker/passive smoker/non smoker.
41 Demographic features Repartition of age at the first collection Gender repartition 50% 40% 30% 43% 38% 48% 37% PNO MPM 69% 31% 20% 17% 10% 0% 1% 0% 25 to 39 yrs 9% 40 to 54 yrs MPM without PNO 55 to 69 yrs 70 to 84 yrs PNO MPM 4% 3% 85 to 99 yrs MPM without PNO 77% 23% 0% 20% 40% 60% 80% 100% Male Female MPM without PNO (2426) PNO MPM (35) Comparison tests Median age (yrs) [Range] 70 [27-97] 67 [40-87] P=0.26 Gender (%) Sex ratio (M/F) 3 2 P=0.26
42 Exposition factors Overall population Asbestos exposure known Yes (% known) No (% known) MPM without PNO 2426 N= (75%) 325 (25%) PNO MPM N= (70%) 10 (30%) Smoking history known Current smoker (% known) Former smoker (% known) Non smoker (% known) N= (22%) 8 (36%) 5 (22%) [10 to 42 PY] [20 to 55 PY]
44 Histological features Overall population MPM without PNO 2426 PNO MPM 35 Comparison test WHO Classification Epithelioid type Biphasic type Sarcomatoid PNO MPM (35) type Desmoplastic type MPM w ithout PNO (2426) (77%) 32 (91%) 289 (12%) 1 (3%) 91% 189 (8%) 1 (3%) 73 (3%) 1 (3%) 77% 12% 8% 3% 3% P=0.24 3% Epithelioid Biphasic 3% Sarcomatoid Desmoplastic 0% 20% 40% 60% 80% 100%
45 Histological features They were epithelioid type in 32 cases, biphasic, desmoplastic and sarcomatoid in one each. Invasion of lung parenchyma was present in all. Major trabecular component parallel to the surface (29), or tubulopapillary (4), macro/microcystic (2) were noted. Necrosis was present in (2). Fistulae between distal alveoli and pleural cavity were present in two cases. Reactive eosinophilic pleuritis was present in 3 cases.
46 Trabecular pattern n=29/35
47 Alveolar invasion Invasion of parietal fat KL-1
48 Pathogenic mechanisms
49 Overall survival Population collected in first between Jan and Dec % 75% 50% PNO MPM 25% 0% Logrank test: p<0.001 MPM without PNO Patients at risk Months since first collection PNO MPM MPM without PNO Plateform presentation USCAP meeting San Diego, 2007
50 Conclusion Mesothelioma presenting as spontaneous PNO is a rare event and may be misdiagnosed Hillerdall G PNO/DMPM 1/ % Br J Dis Chest 1983, 77: 321 Mesonat PNO/DMPM 35/ % Spontaneous or recurrent pneumothorax in a patient over 40 years with a history of asbestos exposure should raise the suspicion of MPM. The mechanisms most frequently discussed is the invasion of the visceral pleura and distal lung by the mesothelial cells resulting in a bronchiolo-pleural fistula.
52 Immunohistochemical markers affecting prognosis p53 87 DMM cases were retrieved from the files of the PNSM with follow up [Period time ]. Additionnally 23 WDPM were collected from the files of the Mesopath group with follow up- Period of time Mutation DMM n = 42 absence of mutation WDPM n = 23 absence of mutation p53 expression (>25% nuclear staining) DMM n= 84 84% WDPM n=23 0% Is there a correlation between the expression of p53 and histological subtype in DMM. Is there a correlation between the expression of p53 and AE in DMM. p= 0.51 ns p= 0.15 ns Epidermal growhth factor receptor (EGFR) Platelet derived growth factor (PDGF)
53 Immunohistochemical markers affecting prognosis p27 p27 ( kinase inhibitor protein- Kip) is a cyclin dependant kinase inhibitor which blocks the cell cycle by binding E/CdK2 complex which prevent progression of the cell cycle from the G1 to the S phase. p 27 loss decreases tumour suppressive activity Beer et al, Histopathology, 2001; 38: Bongiovanni et al, Cancer, 2001;92: Results: Low p27 expression is associated with shorter survival [4-6 months ] compared with high expression [10-11months] Cox-2 Cox 2 has been implicated in carcinogenesis through the down regulation of cell mediated immunity, promotion of angiogenesis, inhibition of apoptosis and the formation of carcinogenic metabolites Edwards et al, Clin Cancer Res 2002;8: Baldi et al, Thorax 2007; 59: Results: Low expression of p27 associated with High expression of Cox-2 correlated with poor prognosis.
54 Immunohistochemical markers affecting prognosis p53 pathways in mesothelioma p53 87 DMM cases were retrieved from the files of the PNSM with follow up [Period time ]. 23 WDPM were collected from the files of the Mesopath group with follow up- Period of time Mutation DMM n = 42 absence of mutation WDPM n = 23 absence of mutation p53 expression EM BM SM DM p53 expression (>25% nuclear staining) DMM n= 84 84% WDPM n=23 0% Is there a correlation between the expression of p53 and histological subtype in DMM? p= 0.15 ns Is there a correlation between the expression of p53 and AE in DMM? p= 0.51 ns 0 1 E E- 14 1
55 Is p53 expression could be a prognostic factor in DMM? test Khi2 DF Pr>Khi2 Log rank
56 Immunohistochemical marker affecting prognosis EGFR Edwards results n=74 patients EGFR overexpression 44% A better survival is observed with EGFR expression, epithelioïd type p<0.0001, PS p<0.000, Absence of chest pain p<0.001 Univariate EGFR expression is a good prognostic factor p=0.01 Multivariate analysis effect of EGFR expression is still independent good prognostic factor p< MESOPATH results n=100 patients Certification Mesopath Status of asbestos exposure EGFR overexpression in 88% Univariate analysis showed a better survival for young age p<0.05, epithelioid type p<0.01, no exposure p<0.05and EGFR expression p<0.01 Multivariate analysis; the effect on survival for EGFR was still significant (p<0.05) even after adjustment for histological type. Our study failed to detect mutation of EGFR ( 30 cases)
57 Genomic profile affecting prognosis Gordon et al J Nat Cancer Inst 2005;95: using oligonucleotide microarrays found fourgene expression ratio test predicted the treatment related patient outcome in MM independently from histological subtype Pass et al Clin Cancer Res; ; 2004:10: using U95 Affymetrix gene chip found that 27 gene classifier predicted prognosis with 95% accuracy Lopez Rios et al Cancer Res 2006;66: design a study for a critical evaluation o microarray based prognostic prediction. The power of microarray in the clinical prognostication has been overestimated
58 Conclusion Mesothelioma is a an heterogeneous disease with a dismal prognosis. In the past few years, there have been some advances in the management of patients with DMM and new molecular alterations have been reported providing broader insights into its biology and leading to the identification of possible new targets for therapy. The need for a better staging and more accurate histological classification leading to a strong selection of good and worst prognostic group will lead to improvement in the management of patients. Among these prognostic factors histopathological classification as a first step is crucial.
59 Nolwen Le Stang A. de Quillacq V. Abonnet S. Lecot F. Morlais J. Hoyez P. Rolland P. Brochard JC. Pairon P. Astoul A. Ilg soit Gilg M. Letourneux G. Launoy E. Imbernon M. Goldberg Goldberg National Health Institute of Surveillance [InVS] Acknowledgments I Abdalsamad H.Begueret E Brambilla F Capron MC Copin AY Delajartre A.Foulet-Rogé A de Mascarel L Garbe O Groussard R Loire JM Piquenot F Thivolet JM Vignaud
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-Bron
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleural
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 email@example.com
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis . Most are
Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Introduction 3 cavities with the same embryologic origin the mesoderme Pleura Exudates Pleura Peritoneum Pericardium 22%
The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics
3-F. Pathology of Mesothelioma Kouki Inai Professor of Department of Pathology, Graduate School of Biomedical Science, Hiroshima University Introduction Mesothelioma is a peculiar type of malignancy, which
Pleura Visceral pleura covers lungs and extends into fissures Parietal pleura limits mediastinum and covers dome of diaphragm and inner aspect of chest wall. Two layers between them (pleural cavity) contains
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital
Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines Wieneke Buikhuisen The Netherlands Cancer Institute Amsterdam The Netherlands Case (1) Male, 56 year
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
Case based applications part III Los Angeles Society Of Pathologists January 25, 2014 Sanja Dacic, MD, PhD University of Pittsburgh Medical Center 1 CASE 1 A 44-year-old woman with multiple lung nodules.
The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericytic
Pathology of Malignant Mesothelioma Françoise Galateau-Sallé Pathology of Malignant Mesothelioma With 169 Figures, 158 in Full Color International Mesothelioma Panel Elisabeth Brambilla, Philip T. Cagle,
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
: Clinicobiological database on mesothelioma ITMO Santé publique Lyon Prof. Françoise Galateau Sallé Professor of Pathology, Centre Leon Bérard (French cancer center), Lyon, France OVERVIEW AT A GLANCE
Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
PERITONEAL MALIGNANT MESOTHELIOMA: A RARE S. R. Dhamotharan 1, S. Shanthi Nirmala 2, F. Celine Foustina Mary 3, M. Arul Raj Kumar 4, R. Vinothprabhu 5 HOW TO CITE THIS ARTICLE: S. R. Dhamotharan, S. Shanthi
Malignant Mesothelioma Recent Advances Dr AS Paul 04 Aug 06 DM Seminar Malignant mesothelioma A tumour of serosal surfaces Pleura, peritoneum Increasing incidence worldwide Association with asbestos exposure
Today s Topics Tumors of the Peritoneum in Women Charles Zaloudek, M.D. Department of Pathology 505 Parnassus Ave., M563 University of California, San Francisco San Francisco, CA USA firstname.lastname@example.org
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
Specialty conference, USCAP San Diego Pulmonary Pathology Sunday march 25, 2007 Case n 3 Francoise Galateau-Salle 1,2,3, Centre Hospitalier Universitaire Caen,, France ERI 3 INSERM 1 MESONAT Registry 2
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia
New Insights into Merkel Cell Carcinoma Bruce R. Smoller, MD Professor and Chair, Department of Pathology Professor, Department of Dermatology University of Arkansas for Medical Sciences Merkel cell carcinoma
A Cytokeratin- and Calretinin-negative Staining Sarcomatoid Malignant Mesothelioma MICHAEL G. HURTUK and MICHELE CARBONE Cardinal Bernadin Cancer Center, Cancer Immunology Program, Department of Pathology,
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
Lessons learned from the Western Australian experience with mesothelioma Alison Reid, Western Australian Institute for Medical Research In partnership with Nick de Klerk, Nola Olsen, Jan Sleith, Geoffrey
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing
This information is an extract from the booklet Understanding mesothelioma. You may find the full booklet helpful. We can send you a free copy see page 5. Contents Introduction Pleural mesothelioma Peritoneal
Volume 2013, Article ID 198729, 4 pages http://dx.doi.org/10.1155/2013/198729 Case Report Pleural Mesothelioma Presenting as Periumbilical Metastasis: The First Clinical Documentation R. F. Falkenstern-Ge,
Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologic
Effusions of the Serous Cavities Annika Dejmek Professor/Consultant in Cytopathology Clinical Pathology; Department of Laboratory Medicine, Malmö, Lund University 5th EFCS Tutorial Trondheim 2012 Pleura
PLEURA- LESIONS LESIONS OF PLEURA Primary Intra pleural bacterial infections Neoplasm (mesothelioma) Secondary A complication of some underlying disease PLEURAL EFFUSION Common manifestation of both primary
Cytological Diagnosis of Malignant Pleural Mesothelioma: A Cautionary Note for Lawyers in Asbestos Litigation Edward Casmere and Joshua Lee Law360 March 7, 2014 For a variety of reasons, lawyers in asbestos
Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Mesothelioma: Questions
Renal tumours WHO 4 MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER Molecular differential pathology of renal cell tumours G. KOVACS A CLASSIFICATION BASED ON UNDERSTANDING THE GENETIC
Setting research priorities for mesothelioma workshop 10 th November 2014 Pre-workshop exercise Your individual ranking of unanswered questions about the diagnosis, treatment and care of mesothelioma Please
Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation www.curemeso.org Delivering the Diagnosis Delivering the Diagnosis Day 1 Taking control
Session 3 : Epidemiology and public health Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH) Le Guyader-Peyrou Sandra Bergonie Institut Context:
Introduction Objective Methods Results Conclusion 2 Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma a rare cancer associated with long latency period (i.e. 20 to 40 years),
Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant
Pathology of lung cancer EASO COURSE ON LUNG CANCER AND MESOTHELIOMA DAMASCUS (SYRIA), MAY 3-4, 2007 Gérard ABADJIAN MD Pathologist Associate Professor, Saint Joseph University Pathology Dept. Hôtel-Dieu
International Journal of Case Reports in Medicine Vol. 2013 (2013), Article ID 409830, 15 minipages. DOI:10.5171/2013.409830 www.ibimapublishing.com Copyright 2013 Andrew Thomas Low, Iain Smith and Simon
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
GUIDE TO ASBESTOS LUNG CANCER What Is Asbestos Lung Cancer? Like tobacco smoking, exposure to asbestos can result in the development of lung cancer. Similarly, the risk of developing asbestos induced lung
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental
Anatomic Pathology / Malignant Pleural Mesothelioma Histologic Assessment and Prognostic Factors of Malignant Pleural Mesothelioma Treated With Extrapleural Pneumonectomy Andrea V. Arrossi, MD, 1 E. Lin,
Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: 10.1309/6A30YQHBMTHEJTEM It has been evident for decades that pathology reports
Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.
Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung
What is Mesothelioma? Mesothelioma is a rare type of cancer that develops in the mesothelial cells found in one s body. These cells form membranous linings that surround and protect the body s organs and
Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation Insidious
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
Asbestos Related Diseases Asbestosis Mesothelioma Lung Cancer Pleural Disease Asbestosis and Mesothelioma (LUNG CANCER) Support Group 1800 017 758 www.amsg.com.au ii Helping you and your family through
Personalized Treatment for Malignant Mesothelioma RN Taub (Onc) J Chabot (Surg) A Borczuk (Path) J Sonnet (Surg) M Kluger (Surg) R Fawwaz (Nuc. Med) E Hare (Onc) Columbia University Mesothelioma Center
SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. TRACEY O CONNOR RESEARCH QUESTON Patients with previously diagnosed hematologic
& MALIGNANT PLEURAL MESOTHELIOMA TREATED IN CLINIC FOR PULMONARY DISEASES AND TUBERCULOSIS PODHRASTOVI IN TEN-YEAR PERIOD ( FROM 1998 TO 2007 ) Vesna Čukić*, Aida Ustamujić, Vladimir Lovre, Hasan Žutić,
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
Lung Cancer International Volume 2015, Article ID 590148, 7 pages http://dx.doi.org/10.1155/2015/590148 Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate
Case Reports in Oncological Medicine Volume 2013, Article ID 283601, 4 pages http://dx.doi.org/10.1155/2013/283601 Case Report Primary Pericardial Mesothelioma: A Rare Entity Mohit Godar, 1 Jianhua Liu,
36 Diagnosis of Synovial Sarcoma of the Pleura and Differentiation from Malignant Mesothelioma Amy Powers and Michele Carbone Synovial sarcomas (SSs) are soft tissue tumors that occur primarily in adolescents
BY THE NUMBERS: THE FUTURE OF MESOTHELIOMA IN AMERICA 1 CUTTING-EDGE ISSUES IN ASBESTOS LITIGATION CONFERENCE Scott Masterson Lewis, Brisbois, Bisgaard & Smith, LLP 1180 Peachtree Street, NE, Suite 2900